Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial-Reference-Cited by-同舟云学术

Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial

Published:2016-04 Issue:4 Volume:17 Page:496-508
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Garcia-Manero Guillermo,Fenaux Pierre,Al-Kali Aref,Baer Maria R,Sekeres Mikkael A,Roboz Gail J,Gaidano Gianluca,Scott Bart L,Greenberg Peter,Platzbecker Uwe,Steensma David P,Kambhampati Suman,Kreuzer Karl-Anton,Godley Lucy A,Atallah Ehab,Collins Robert,Kantarjian Hagop,Jabbour Elias,Wilhelm Francois E,Azarnia Nozar,Silverman Lewis R

Publisher

Elsevier BV

Subject

Oncology

Reference33 articles.

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Myelodysplastic Syndromes. Version 1. 2016.

2. Myelodysplastic syndromes: incidence and survival in the United States;Ma;Cancer,2007

3. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys;Sekeres;J Natl Cancer Inst,2008

4. Phase I trial of low-dose oral clofarabine in myelodysplastic syndromes patients who have failed frontline therapy;Rudrapatna;Leuk Res,2015

5. International scoring system for evaluating prognosis in myelodysplastic syndromes;Greenberg;Blood,1997

Cited by 149 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non-kinase off-target inhibitory activities of clinically-relevant kinase inhibitors;European Journal of Medicinal Chemistry;2024-09

2. Osmotic Stress Influences Microtubule Drug Response Via WNK1 Kinase Signaling;2024-07-10

3. Prospective performance of the IWG-2023 criteria and IPSS-M in a phase 2 trial of guadecitabine for higher-risk MDS or CMML;Blood Neoplasia;2024-06

4. Drug screening in human physiologic medium identifies uric acid as an inhibitor of rigosertib efficacy;JCI Insight;2024-05-30

5. Advances in the management of higher-risk myelodysplastic syndromes: future prospects;Leukemia & Lymphoma;2024-05-07